Download MendeleyDiscovery of potent, selective, bioavailable phosphodiesterase 2 (PDE2) inhibitors active in an osteoarthritis pain model, Part I: Transformation of selective pyrazolodiazepinone phosphodiesterase 4 (PDE4) inhibitors into selective PDE2 inhibitors.
Plummer, M.S., Cornicelli, J., Roark, H., Skalitzky, D.J., Stankovic, C.J., Bove, S., Pandit, J., Goodman, A., Hicks, J., Shahripour, A., Beidler, D., Lu, X.K., Sanchez, B., Whitehead, C., Sarver, R., Braden, T., Gowan, R., Shen, X.Q., Welch, K., Ogden, A., Sadagopan, N., Baum, H., Miller, H., Banotai, C., Spessard, C., Lightle, S.(2013) Bioorg Med Chem Lett 23: 3438-3442
- PubMed: 23582272 Search on PubMed
- DOI: https://doi.org/10.1016/j.bmcl.2013.03.072
- Primary Citation Related Structures:
4JIB - PubMed Abstract:
We identified potent, selective PDE2 inhibitors by optimizing residual PDE2 activity in a series of PDE4 inhibitors, while simultaneously minimizing PDE4 activity. These newly designed PDE2 inhibitors bind to the PDE2 enzyme in a cGMP-like mode in contrast to the cAMP-like binding mode found in PDE4. Structure activity relationship studies coupled with an inhibitor bound crystal structure in the active site of the catalytic domain of PDE2 identified structural features required to minimize PDE4 inhibition while simultaneously maximizing PDE2 inhibition.
- Department of Chemistry, Pfizer Global Research and Development, Ann Arbor, MI 48105, USA. marksplummer@gmail.com
Organizational Affiliation:
